Inosine Induces Stemness Features in CAR-T cells and Enhances Potency

Overview
The study shows that inosine induces stemness and metabolic reprogramming in CAR-T cells, improving potency. Clinical-scale manufacturing of GD2-CAR-T cells in inosine-containing media was performed using a semi-closed G-Rex® system.
What this paper found
Adding inosine to culture medium during manufacturing gave human CAR-T cells a stem-like, more potent profile, whereas knocking out CD39, CD73 or the adenosine receptor A2aR changed them only modestly. Overexpressing adenosine deaminase, which converts adenosine to inosine, shifted exhausted GD2 CAR-T cells toward stem-like memory states, and inosine alone reproduced this in vitro with higher CD62L, greater cytokine release and cytotoxicity. Inosine lowered glycolysis, raised glutaminolysis and polyamine synthesis, increased chromatin accessibility at stemness genes, and its stemness effect was lost after EIF5A knockout. In a clinical-scale GD2-CAR run in a semi-closed G-Rex® system, inosine cultures yielded fewer cells (238.5 vs 387.7 × 10^6) yet enough for doses of 1 × 10^6 CAR-T cells/kg, and the products showed greater antitumor activity in mice.
Note: Inosine reduced proliferation, so total cell yields in the clinical-scale cultures were lower than in glucose-based controls.
These results identify INO as a potent modulator of CAR-T cell metabolism and epigenetic stemness programming and deliver an enhanced potency platform for cell manufacturing. — Dorota D. Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A. Freitas, Yiyun Chen, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labanieh, Vimal Keerthi, Amaury Leruste, Malek Bashti, Janette Mata-Alcazar, Nikolaos Gkitsas, Justin A. Guerrero, Chris Fisher, Sunny Patel, Kyle Asano, Shabnum Patel, Kara L. Davis, Ansuman T. Satpathy, Steven A. Feldman, Elena Sotillo, Crystal L. Mackall, Cancer Cell
Study details
- Authors
- Dorota D. Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A. Freitas, Yiyun Chen, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labanieh, Vimal Keerthi, Amaury Leruste, Malek Bashti, Janette Mata-Alcazar, Nikolaos Gkitsas, Justin A. Guerrero, Chris Fisher, Sunny Patel, Kyle Asano, Shabnum Patel, Kara L. Davis, Ansuman T. Satpathy, Steven A. Feldman, Elena Sotillo, Crystal L. Mackall
- Institution
- Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California · Parker Institute for Cancer Immunotherapy, San Francisco, California · Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, California · Department of Medicine, Division of Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, California · Department of Pathology, Stanford University School of Medicine, Stanford, California · Center for Personal Dynamic Regulomes, Stanford University, Stanford, California · Gladstone-UCSF Institute of Genomic Immunology, San Francisco, California
- Journal
- Cancer Cell
- Year
- 2024
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Clinical-grade GD2.bbz-CAR-T cells were manufactured in a semi-closed G-Rex® culture platform from enriched healthy donor T cells. The cells were activated with anti-CD3/CD28 beads and transduced with clinical-grade GD2-CAR vector at an MOI of 10. From day 3 to day 7 they were cultured in standard glucose-containing RPMI or in inosine-containing RPMI without glucose. At day 7, inosine cultures yielded 238.5 × 10^6 total cells versus 387.7 × 10^6 in controls, enough for clinical doses of 1 × 10^6 CAR-T cells/kg body weight, with no difference in transduction efficiency, CD4/CD8 ratio or viability.
Explore related
Full citation
Klysz DD, Fowler C, Malipatlolla M, et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell. 2024;42(2):266-282.e8.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.